首页> 美国卫生研究院文献>Heliyon >Predicting novel drugs for SARS-CoV-2 using machine learning from a 10 million chemical space
【2h】

Predicting novel drugs for SARS-CoV-2 using machine learning from a 10 million chemical space

机译:从A 1000万化学空间的机器学习预测SARS-COV-2的新药

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There is an urgent need for the identification of effective therapeutics for COVID-19 and we have developed a machine learning drug discovery pipeline to identify several drug candidates. First, we collect assay data for 65 target human proteins known to interact with the SARS-CoV-2 proteins, including the ACE2 receptor. Next, we train machine learning models to predict inhibitory activity and use them to screen FDA registered chemicals and approved drugs (~100,000) and ~14 million purchasable chemicals. We filter predictions according to estimated mammalian toxicity and vapor pressure. Prospective volatile candidates are proposed as novel inhaled therapeutics since the nasal cavity and respiratory tracts are early bottlenecks for infection. We also identify candidates that act across multiple targets as promising for future analyses. We anticipate that this theoretical study can accelerate testing of two categories of therapeutics: repurposed drugs suited for short-term approval, and novel efficacious drugs suitable for a long-term follow up.
机译:迫切需要识别Covid-19的有效治疗方法,我们开发了一款机器学习药物发现管道,以识别几个药物候选人。首先,我们收集已知65个靶蛋白质的测定数据,该蛋白已知与SARS-COV-2蛋白相互作用,包括ACE2受体。接下来,我们培训机器学习模型以预测抑制活动,并使用它们来筛选FDA注册化学品和批准的药物(〜100,000)和约1400万可购买的化学品。根据估计的哺乳动物毒性和蒸汽压力过滤预测。提出前瞻性挥发性候选人作为新型吸入治疗剂,因为鼻腔和呼吸道是感染的早期瓶颈。我们还确定候选人,以跨多个目标行事,因为未来的分析是有希望的。我们预计这项理论研究可以加速两类治疗药物的测试:可重复的药物适用于短期批准的药物,以及适合长期随访的新型有效药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号